Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 19 Kidney Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 4 Neoplasm Metastasis 2 Recurrence 1 Pheochromocytoma 1 Paraganglioma 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Glioblastoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

pembrolizumab 133 Gemcitabine 101 Paclitaxel 100 Carboplatin 84 Nivolumab 66 Docetaxel 62 Bevacizumab 62 Cisplatin 57 Pemetrexed 50 Fluorouracil 49 Cyclophosphamide 41 Cetuximab 41 trametinib 38 venetoclax 37 Leucovorin 37 Irinotecan 37 Sorafenib 35 Capecitabine 35 Ipilimumab 33 Dexamethasone 32 atezolizumab 31 Erlotinib Hydrochloride 28 130-nm albumin-bound paclitaxel 28 Drug Therapy 27 Epoetin Alfa 26 Doxorubicin 25 Oxaliplatin 24 Albumin-Bound Paclitaxel 24 Prednisone 23 Rituximab 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasms × belzutifan × Clear all

NCT04976634 2025-04-06

MK-6482-016

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡